We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Residual Inflammatory Risk Associated With Interleukin-18 and Interleukin-6 After Successful Interleukin-1β Inhibition With Canakinumab: Further Rationale for the Development of Targeted Anti-Cytokine Therapies for the Treatment of Atherothrombosis
Eur Heart J 2019 Sep 01;[EPub Ahead of Print], PM Ridker, JG MacFadyen, T Thuren, P Libby